Neurodegenerative Disease Therapeutics Industry | Forecast 2030
Neurodegenerative Disease Therapeutics Industry Data Book Covers Parkinson’s Disease Treatment and Alzheimer's Therapeutics Markets.
The global neurodegenerative disease markets combine to account for USD 8.33 billion revenue in 2021, which is expected to reach USD 28.15 billion by 2030, growing at a cumulative rate of 15.6% over the forecast period.
Grand View Research’s neurodegenerative disease therapeutics industry data book is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.
Parkinson’s Disease Treatment Market Insights
The global Parkinson’s disease treatment market size was valued at USD 4.28 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 12.1% from 2022 to 2030.
The Carbidopa-levodopa drug class segment dominated the industry with a revenue share of more than 25.00% in 2021. This growth was attributed to the high prescription rate of these drugs. According to the U.S. Drug Use Statistics, the estimated number of Carbidopa-Levodopa prescriptions was found to be 527,530 for 183,690 Parkinson’s patients in 2020.
The retail pharmacy segment dominated the global industry in 2021 and accounted for the largest share of 59.10% of the overall revenue. The segment is anticipated to expand further at the fastest growth rate during the forecast period. According to Parkinson’s news today, PD affects around 41 individuals per 100,000 in their 40s, to more than 1,900 people per 100,000 in their 80s and 90s. It is the second-most common neurodegenerative disorder after Alzheimer’s disease.
Furthermore, the ease of availability of PD drugs including generic carbidopa-levodopa, pramipexole dihydrochloride, selegiline hydrochloride, and others in retail pharmacy chains, such as Walgreens and Walmart Stores, boosts the segment growth. The online pharmacy segment is expected to witness a significant growth rate during the forecast period.
Access the Global Neurodegenerative Disease Therapeutics Industry Data Book, 2022 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competition benchmarking, macro-environmental analyses, and regulatory & technological framework studies
Alzheimer's Therapeutics Market Insights
The global Alzheimer's therapeutics market size was valued at USD 4.04 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 16.2% from 2022 to 2030.
The cholinesterase inhibitors segment held the largest revenue share of over 50.0% in 2021 as it is the standard of care for Alzheimer’s treatment. In March 2022, the U.S. FDA approved the cholinesterase inhibitor Adlarity (donepezil hydrochloride) developed by Corium Inc., for the treatment of patients with severe dementia of Alzheimer’s disease (AD).
The pipeline drugs segment is expected to witness the fastest growth over the forecast period owing to the impending launch of multiple disease-modifying therapies. Companies such as F. Hoffmann La Roche Ltd.; Biogen/Eisai Inc.; and Eli Lilly and Company have drug candidates under development that will modify the treatment landscape of AD.
The hospital pharmacy segment dominated the market in 2021 with a revenue share of over 55.0% owing to the increasing hospitalization due to a rise in the geriatric population and Alzheimer’s patients. According to Alzheimer’s Association report 2022, there are 518 hospitalizations per 1,000 Medicare beneficiaries in the geriatric population having Alzheimer’s or other dementias as compared to only 234 hospitalizations per 1,000 Medicare beneficiaries without these conditions. However, the total number of hospitalizations of AD patients is expected to remain low compared to the prevalence of Alzheimer’s disease.
Neurodegenerative Disease Therapeutics Market – Global Industry Segmentation
Neurodegenerative Disease Therapeutics Market - Segment Analysis, By Drug Class
- Parkinson’s Disease TreatmentCarbidopa-Levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT Inhibitors
- Anticholinergics
- Others
- Alzheimer’s TherapeuticsCholinesterase Inhibitors
- NMDA Receptor Antagonist
- Combination Drug
- Pipeline Drugs
Neurodegenerative Disease Therapeutics - Segment Analysis, By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- E-commerce
Order your copy of the Free Sample of “Neurodegenerative Disease Therapeutics Industry Data Book - Parkinson’s Disease Treatment and Alzheimer's Therapeutics Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research
Neurodegenerative Disease Therapeutics Industry Data Book Regional Outlook
- North America
- S.
- Canada
- Europe
- K.
- Germany
- France
- Italy
- Spain
- Russia
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Australia
- Thailand
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Rest of MEA
Neurodegenerative Disease Therapeutics Industry Data Book Competitive Landscape
New product launches and R&D investments are some of the key strategies adopted by the key players to acquire a greater market share.
Key players operating in the neurodegenerative disease therapeutics industry are –
- Eisai Co., Ltd.
- AbbVie Inc. (Allergan Plc.)
- Merck & Co., Inc.
- Adamas Pharmaceuticals, Inc.
- Novartis AG,H. Lundbeck A/S
- Cerevel Therapeutics
- Biogen
- Daiichi Sankyo Company
- Limited
- Hoffmann La Roche Ltd.
- TauRx Pharmaceuticals Ltd.
- Johnson & Johnson Services, Inc.
- AC Immune
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc. (GSK)
Go through the table of content of Neurodegenerative Disease Therapeutics Industry Data Book to get a better understanding of the Coverage & Scope of the study
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
The global Rare Neurodegenerative Disease Treatment Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2020-2027.
Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the rare neurodegenerative disease treatment market include Allergan Plc, Bayer AG, F.Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Rare Neurodegenerative Disease Treatment Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/rare-neurodegenerative-disease-treatment-market/download-sampleMarket DynamicsThe rise in prevalence and increase in demand for newer drugs to treat rare neurological disorders has led to an increase in research & development efforts followed by introducing innovative neurological disorder drugs.
In addition, an increase in demand for neurological disorder drugs for the treatment of Alzheimer’s disease and Parkinson’s disease and a rise in competition between major players are likely to boost the growth of the market.
However, the cost of neurological disorder treatment is considerably high, owing to the large quantity of antiepileptic, anticholinergic, and hypnotic & sedatives required.
This causes problems with movement (Ataxia), or mental functioning (dementia).
The overall Global Neurodegenerative Disease Market is expected to grow at a significant compound CAGR rate of 6.8% from USD 32.65 billion in 2018 to USD 55.26 billion in 2026.
Moreover, increasing occurrence of neurological disorders is providing ample of opportunities.Global Neurodegenerative Disease: Key SegmentsBy Indications: - Amongst indications, Alzheimer’s disease segment captured the largest market share of the global market due to Alzheimer's disease (AD) is the most widely neurodegenerative disease.
Hallmark pathohistological findings of AD include widespread neuronal degeneration, extracellular amyloid plaques and intracellular neurofibrillary tangles (NFT) different lines of evidence indicate that AD grows primarily as the result of an amyloid cascade.By Drug class: - Amongst Drug class, SSRIs segment captured the largest market share of the global market due to Sertraline (Zoloft) is a particular serotonin reuptake inhibitor (SSRI) that is generally prescribed as an antidepressant and proposed as a potential first-line medication to treat individuals with major depression.
North America region dominated the Neurodegenerative Disease market owing to the development of medical infrastructure and half of the world’s procedures being done in the U.S. because of high medical reimbursement facilities and technological advancement.
Additionally, there are a large number of patients who go undetected.
